Can Ozempic or other GLP-1 drugs slow Parkinson's?

Can Ozempic or other GLP-1 drugs slow Parkinson's?

No clinical trials show that semaglutide halts or slows the underlying progression of Parkinson's disease. Semaglutide, the drug sold as Ozempic, is only being evaluated in an ongoing trial, but that is currently just a trial registration under ClinicalTrials.gov number NCT03659682. Because this trial has not yet reported any results, there are no human data to show whether semaglutide works for Parkinson's disease.

Exenatide, the most heavily researched drug in this class, failed to show any benefit in its largest and longest trial. A phase 3 trial evaluated weekly exenatide in 194 participants over 96 weeks. At the end of the trial, movement scores on the MDS-UPDRS part III scale, a clinician-rated movement test where higher numbers indicate worse movement, showed no significant differences when patients were off-medication. This trial refuted earlier, weaker findings from an open-label study of 45 participants and a small 60-week trial of 62 participants.

Lixisenatide showed modest motor benefits in a phase 2 trial, but the evidence remains weak and did not translate into daily improvements. The LIXIPARK trial evaluated 156 participants with early Parkinson's disease. At 12 months, motor scores on the movement scale improved by 0.04 points in the lixisenatide group and worsened by 3.04 points in the placebo group. However, this small benefit did not improve everyday activities, and 46 per cent of participants suffered from nausea.

Systematic reviews of these trials have concluded that the class as a whole does not offer disease-modifying benefits. A meta-analysis of five randomised controlled trials involving 708 participants showed no statistically significant differences in motor function. Instead, these treatments significantly increased the risk of gastrointestinal side effects.

What did the trials of exenatide and lixisenatide actually find?

Mid-stage trials of older GLP-1 drugs show conflicting results on Parkinson's motor symptoms. The earliest randomised trials of exenatide and lixisenatide reported small but statistically significant differences in movement scores compared to placebo, but these studies were limited by small sample sizes. A subsequent larger phase 3 trial of exenatide found no motor benefit at all.

The first randomised trial of exenatide was open-label and lacked a placebo control. This pilot study evaluated 45 participants with moderately severe Parkinson's disease. After 12 months, the treated group had a movement score that was 4.9 points lower, indicating improved movement, compared to the untreated group. Because this trial was open-label, meaning participants and doctors knew who was receiving the active drug, the risk of a placebo effect inflating the benefits remains high.

A double-blind phase 2 trial of exenatide showed a modest motor benefit at 60 weeks. This trial assigned 32 participants to weekly injections of exenatide and 30 participants to a placebo for 48 weeks, followed by a 12-week washout period, a drug-free window designed to see if the therapeutic benefits remain after treatment stops. At 60 weeks, off-medication motor scores improved by 1.0 point in the exenatide group and worsened by 2.1 points in the placebo group.

The lixisenatide phase 2 trial showed less motor decline over 12 months. This trial enrolled 156 participants diagnosed with early Parkinson's disease. At 12 months, on-medication movement scores had improved by 0.04 points in the lixisenatide group and worsened by 3.04 points in the placebo group. Liraglutide has only been evaluated in a preprint that is not yet peer-reviewed, which reported that the drug had no clear effect on overall motor severity.

Does a small difference on a motor test mean brain cells are being saved?

Temporary improvement on a motor scale fails to prove a drug stops brain cell loss. This is due to a carry-over effect, which occurs when the symptom-relieving benefits of a treatment persist even after the drug has been stopped. If the washout period, the scheduled window of time where a patient stops taking a drug before clinical evaluation, is too short, these lingering benefits are easily mistaken for a permanent slowing of the disease.

The duration of a drug's symptomatic effect varies wildly by drug and by patient. In the DATATOP trial, a washout period of 4 to 8 weeks proved inadequate because the drug selegiline permanently blocks an enzyme, meaning its effects only fade when the brain slowly produces new ones. Similarly, in a trial of exenatide, patients still showed improvement after a two-month washout, but researchers acknowledged this could represent a prolonged symptom-masking effect rather than physical protection of brain cells.

Withdrawing treatment to test patients off-medication forces many to drop out of trials. When patients are taken off their therapies, their movement symptoms can rapidly relapse. In one trial, only 38 out of 54 participants successfully completed the washout period, while another 6 withdrew because they needed to resume treatment.

Excluding these dropped-out patients severely distorts trial results. If researchers only analyse the scores of patients who managed to complete the washout, the final data becomes heavily biased in favour of those who did not experience a significant relapse. Because there is no clinical consensus on how to handle this missing data, temporary improvements on off-medication scales remain highly unreliable measures of disease modification.

Is Ozempic itself being tested in people with Parkinson's?

No human clinical trial results have been published for semaglutide in Parkinson's disease. The drug is currently being evaluated in an ongoing trial, but that is currently just a trial registration under number NCT03659682. Because this trial has not yet reported any results, there are no human data to show whether semaglutide works for Parkinson's disease.

Semaglutide presents unique tolerability concerns compared to other drugs in its class. It has a much greater potency for causing weight loss than other tested therapies. This makes weight loss a major safety issue, particularly for patients who begin with a low body mass index, which is a measure of body fat.

A drug engineered specifically to cross into the brain failed to show any benefit. The drug NLY01 is a longer-lasting version of exenatide designed to improve brain penetration. It was tested in a 36-week phase 2 trial involving 255 participants, where 85 received a low dose, 85 a high dose, and 85 a placebo. At the end of the trial, neither dose of the drug showed any motor or non-motor improvements compared to the placebo.

Other drugs have shown only highly restricted effects. Liraglutide was evaluated in a study that has only been reported as a preprint, meaning the paper has not yet been peer-reviewed. In that study, liraglutide improved quality of life but had no clear impact on motor severity or thinking skills. When researchers pool the data from all five completed randomized controlled trials in meta-analyses, they find no statistically significant overall benefits.

What side effects appeared when people with Parkinson's took these drugs?

Gastrointestinal complications dominate the safety profile of these diabetes drugs in Parkinson’s clinical trials. A meta-analysis combining five randomised trials involving 708 participants found that nausea was significantly increased in treated patients, representing an absolute increase of 253 cases per 1,000 patients. Vomiting was highly elevated, and constipation risks increased, which is a particular concern because delayed gut transit already affects about 50 per cent of people with Parkinson's.

Weight loss is a frequent and clinically concerning consequence of these treatments. Across the trials, weight loss was significantly more common in the treated groups, translating to an absolute increase of 210 cases per 1,000 patients. Although losing weight is a desired target for diabetes or obesity, in Parkinson’s disease it represents a hazard that can trigger muscle wasting and physical frailty.

Poor tolerability led to a higher rate of patients dropping out of treatment. Taking these drugs led to an absolute increase of 59 treatment discontinuations due to adverse events per 1,000 patients compared to a placebo. In a 96-week trial of weekly exenatide involving 194 patients, 12 participants on the drug withdrew from the trial entirely, whereas only four in the placebo group withdrew.

Few serious adverse events were uniquely tied to the drugs. One serious case of pancreatitis, a painful inflammation of the pancreas, occurred in the lixisenatide trial. Other side effects, such as anxiety, fatigue, headaches, or low blood sugar, did not show any statistically significant differences between the groups. Interestingly, treated patients actually experienced slightly fewer falls.

What this does not show

Current evidence fails to show that these diabetes drugs can slow the progression of Parkinson's disease. Despite promising laboratory studies, human trials have produced highly inconsistent results and failed to show clear, replicable clinical benefits. Systematic reviews of the existing trials show no overall improvement in either motor or non-motor symptoms of the disease.

The largest Phase 3 trial to date found no benefit whatsoever. In the Exenatide-PD3 trial, researchers randomised 194 patients with moderate Parkinson's disease to receive either a weekly 2 mg injection of exenatide or a placebo for 96 weeks. At the end of the trial, motor function off medication showed no statistical difference between the treatments, and the trial currently carries a published Expression of Concern in the Lancet medical journal.

Promising claims about semaglutide rest on a trial that has not reported. The trial registration NCT03659682 is a clinical trial registration for an ongoing phase 2 study of semaglutide in people with Parkinson's disease. No clinical results have been published from this registered trial yet, leaving it completely unknown whether the drug works in humans.

Another long-acting formulation completely failed to improve patient outcomes. In a trial of NLY01, a version of exenatide designed to improve brain penetration, researchers randomised 255 participants with early untreated Parkinson's disease across 58 clinics. At the end of 36 weeks, neither the 2.5 mg nor the 5.0 mg dose of the drug showed any improvement in motor or non-motor symptoms compared with the placebo. Positive claims also rely on the LIXIPARK trial of lixisenatide, which caused nausea in 46 per cent of participants and has been the subject of published scientific disagreements.

This review provides the exact participant numbers, trial designs, and safety risks from completed human studies of GLP-1 drugs. You can use these facts to discuss with your specialist whether the high rates of side effects and lack of proven benefit make these treatments unsuitable for your specific symptoms.